VivoSim Labs, Inc. VIVS PHARMA

Healthcare · Biotechnology · United States

https://vivosim.ai

Company Profile ↓

$0.28

-84.81% 1Y

Mkt Cap$3.75M

P/E-0.06

P/B-0.31

52W High$4.78

52W Low$0.28

Book Value$-0.73

EPS (TTM)$-4.46

Company Overview

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Recent Developments

Mar 2026 Revenue of $131.00K (-9.0% YoY); net profit $-13.84M.
Trailing 12 Months Year-on-year growth — revenue -51.4%.
5-Year Trend Long-term compounding — revenue CAGR -14.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-14.27%
1 Year:	-51.40%

Stock Price Performance

1 Year:	-84.81%
6 Months:	-84.56%
3 Months:	-76.45%
1 Month:	-14.36%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 0% of range

$0.28 $4.78

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)31.20 · Neutral

Price Performance

1M-14.36%

3M-76.45%

6M-84.56%

1Y-84.81%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -14.3% CAGR over 5 years.
Trading 94.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.06

Industry PE

24.83

Forward P/E

PEG Ratio

Book Value

$-0.73

Price to Book

-0.31

P/S

27.14

EV/EBITDA

-0.18

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-14.27%

Profit 5Y

Revenue (YoY)

-51.40%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-89.50%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-1.03

EPS (TTM)

$-4.46

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.90

Current Ratio

1.70

Debt

$316.00K

Total Assets

$7.39M

Current Assets

$6.63M

Working Capital

$3.84M

Ownership

Promoter Holding

2.67%

Chg in Prom Hold

0.06%

FII / Inst Holding

11.09%

Chg in FII Hold

9.70%

Financial Snapshot

Enterprise Value

$3.75M

Total Revenue (TTM)

$112.00K

EBITDA

$-11.14M

Free Cash Flow

$-7.58M

Operating Cash Flow

$-10.10M

Shares Outstanding

13.39M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VIVS VivoSim Labs, Inc. PHARMA	0.28	-0.06	$3.75M	0.00%	-	-	-14.27%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Jun 2019	Sep 2019	Dec 2019	Jun 2020	Sep 2020	Dec 2020	Jun 2021	Sep 2021	Dec 2021	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	990.00K	1.35M	1.15M	-	689.00K	943.00K	779.00K	668.00K	1.23M	298.00K	0	0	0	-	0	0	0	77.00K	131.00K	75.00K	0	5.00K	39.00K	30.00K	-	51.00K	37.00K	28.00K	26.00K	40.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	51.00K	37.00K	28.00K	26.00K	40.00K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.21M	2.95M	2.66M	2.78M	3.23M
Operating Income	-6.96M	-	-8.46M	-11.28M	-10.47M	-	-8.78M	-9.48M	-9.63M	-	-10.20M	-9.58M	-7.91M	-	-7.58M	-6.01M	-6.53M	-6.52M	-6.83M	-5.23M	-2.79M	-8.95M	-2.49M	-2.56M	-3.51M	-3.50M	-3.24M	-3.35M	-3.36M	-4.20M	-4.12M	-3.68M	-3.39M	-2.61M	-	-3.15M	-2.92M	-2.63M	-2.75M	-3.19M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.92M	-2.78M	-2.48M	-2.63M	-5.72M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00K	4.00K	0	4.00K	4.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.85M	-2.84M	-2.54M	-2.69M	-5.76M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2.00K	0	0
Net Income	-6.99M	-7.80M	-8.49M	-11.26M	-10.46M	-8.37M	-8.77M	-9.44M	-9.58M	-10.66M	-10.10M	-9.46M	-7.79M	-7.45M	-7.42M	-5.84M	-6.40M	-6.32M	-6.29M	-3.37M	-2.77M	-8.95M	-2.51M	-2.53M	-3.50M	-3.50M	-3.21M	-3.32M	-3.26M	-4.03M	-3.99M	-3.60M	-3.34M	-2.55M	-	6.85M	-2.84M	-2.54M	-2.69M	-5.76M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.29	-0.40	-0.40	-0.37	-0.38	-0.37	-0.46	-0.46	-0.40	-2.74	-1.68	-2.28	-	-1.14	-0.98	-1.03	-
R&D Expense	3.24M	-	4.14M	4.74M	4.59M	-	4.44M	4.54M	5.02M	-	5.03M	4.94M	4.00M	-	3.38M	3.19M	3.78M	3.82M	1.45M	145.00K	0	28.00K	402.00K	580.00K	679.00K	926.00K	1.02M	1.23M	1.19M	1.67M	1.33M	1.43M	1.40M	984.00K	1.78M	-	1.00M	923.00K	1.14M	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	969.00K	1.20M	379.00K	571.00K	1.48M	4.23M	4.60M	3.09M	2.20M	0	-	370.00K	109.00K	144.00K	131.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	0	5.00K	0
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	109.00K	139.00K	131.00K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	18.10M	15.20M	12.76M	11.62M
Operating Income	-2.31M	-9.32M	-20.65M	-30.30M	-38.64M	-38.58M	-35.27M	-27.27M	-21.48M	-16.83M	-	-17.73M	-15.09M	-12.62M	-11.49M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-17.44M	-14.39M	-2.21M	-13.61M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	0	10.00K	12.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-17.26M	-14.67M	-2.49M	-13.84M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	2.00K	2.00K	2.00K	2.00K
Net Income	-	-43.55M	-25.85M	-30.08M	-38.58M	-38.45M	-34.80M	-26.64M	-18.71M	-16.83M	-	-17.26M	-14.67M	-2.49M	-13.84M
Diluted EPS	-0.19	-0.97	-	-	-	-	-	-	-	-	-	-23.76	-19.25	-1.70	-5.35
R&D Expense	1.42M	3.44M	7.97M	12.92M	18.01M	19.55M	17.96M	14.75M	5.28M	1.10M	3.32M	8.88M	5.50M	5.03M	4.19M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Mar 2012	Dec 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Dec 2024	Mar 2025	Mar 2026
Total Assets	-	-	-	1.41M	-	16.75M	17.38M	50.19M	53.49M	67.58M	69.18M	49.83M	40.62M	28.44M	39.92M	-	20.31M	6.35M	-	14.65M	7.39M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.05M	3.94M	-	12.13M	6.63M
Cash & Equivalents	-	-	285.00K	340.00K	10.35M	14.82M	15.63M	48.17M	50.14M	62.09M	62.75M	43.73M	36.48M	27.36M	37.36M	-	15.30M	2.90M	-	11.31M	5.02M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	297.00K	-	0	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	152.00K	33.00K	-	30.00K	32.00K
Total Liabilities	-	-	-	3.24M	-	22.05M	8.41M	1.90M	4.79M	5.39M	6.82M	5.24M	4.33M	1.81M	721.00K	-	4.98M	2.75M	-	4.16M	8.48M
Current Liabilities	-	-	-	1.98M	-	22.04M	8.38M	1.89M	4.76M	4.49M	6.01M	4.66M	3.74M	1.81M	721.00K	-	3.67M	1.86M	-	3.74M	2.79M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.80M	1.39M	-	942.00K	447.00K
Total Equity	-96.00K	-966.00K	-2.30M	-1.83M	-	-5.30M	8.97M	48.28M	48.70M	62.18M	62.36M	44.59M	36.30M	26.63M	39.20M	-	15.33M	3.60M	364.00K	10.49M	-1.10M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	726.41K	839.81K	-	1.90M	2.89M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-1.91M	-9.69M	-15.56M	-	-	-	-28.86M	-20.38M	-14.88M	-13.32M	-	-12.41M	-14.65M	-9.46M	-10.83M
Investing Cash Flow	-111.00K	-445.00K	-	-	-	-	-292.00K	-76.00K	747.00K	-393.00K	-	-966.00K	816.00K	9.03M	94.00K
Financing Cash Flow	2.08M	24.61M	-	-	-	-	10.11M	13.15M	4.93M	23.84M	-	0	1.44M	8.85M	4.45M
Capital Expenditure	-46.00K	-357.00K	-277.00K	-1.52M	-2.11M	-1.35M	-226.00K	-79.00K	-0	-405.00K	-409.00K	-396.00K	-42.00K	-13.00K	-
Free Cash Flow	-1.96M	-10.05M	-15.84M	-	-	-	-29.08M	-20.45M	-14.88M	-13.73M	-	-12.80M	-14.70M	-9.47M	-10.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-13.37M	-12.40M	8.41M	-6.29M
Share Buybacks	-	-	-	-	-	-	-	-	0	1.00K	0	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	100.0%	96.5%	100.0%
Operating Margin %	-237.9%	-778.5%	-5,448.3%	-5,306.0%	-2,605.7%	-911.9%	-766.3%	-882.4%	-977.9%	-	-	-4,792.2%	-13,840.4%	-8,761.1%	-8,768.7%
Net Margin %	-	-3,638.5%	-6,820.1%	-5,268.3%	-2,601.1%	-908.9%	-756.1%	-861.7%	-852.0%	-	-	-4,664.6%	-13,459.6%	-1,727.8%	-10,567.2%
ROE %	-	821.3%	-53.5%	-61.8%	-62.0%	-61.7%	-78.1%	-73.4%	-70.3%	-42.9%	-	-112.6%	-407.4%	-23.7%	1,259.6%
ROCE %	405.8%	176.3%	-42.8%	-62.2%	-61.3%	-61.1%	-78.1%	-73.9%	-80.6%	-42.9%	-	-106.5%	-336.1%	-115.6%	-249.7%

Shareholding Pattern

Insiders

2.67%

Institutions

11.09%

Public Float

11.39%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Geode Capital Management, LLC	0.16%	25.98K	$5.90K
2	Renaissance Technologies, LLC	0.11%	18.50K	$4.20K
3	HRT Financial LP	0.11%	18.32K	$4.16K
4	Vanguard Capital Management LLC	0.09%	15.37K	$3.49K
5	Blackrock Inc.	0.07%	11.82K	$2.68K
6	Vanguard Fiduciary Trust Co	0.04%	7.00K	$1.59K
7	Tower Research Capital LLC (TRC)	0.03%	5.25K	$1.19K
8	SBI Securities Co., Ltd.	-	221	$50
9	FNY Investment Advisers, LLC	-	200	$45
10	Larson Financial Group LLC	-	166	$37

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VIVS

Google News hu, 03 Sep 2026

VivoSim Labs (VIVS) News Flow - Moomoo

<a href="https://news.google.com/rss/articles/CBMikgNBVV95cUxNQzFQaEJsVUhaeE1rOURya1RTMFBQbHFDOEVzRVc3aDVmR3dpV00yemY4TGFEakFsMlNPb21wMVdXWU9mOVIzQzFab0h1VXZLSjRUcmpKcEdLSkNsWVZaS2NMY3R5OHBuOXB0WDhTa1p3UXlvV1EyWkxtN3BPSEFOVm44RjhnSkNybzYtWD…

Google News Fri, 21 Aug 2026

VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQaTE5V01YOWppYlBUT0c2WnA4ZGpLVjNxeUYyZEF1OWZqN1R0aUVHelZadm5tYVhxRG5hbnJCY1o5SkxOX1NnSkJfcUlFQlhSSzA0czJCcE1hbkp4UGVFME4wMkJJa0VQaWRvSW5vRHVYQkpTUE8xME1STVl1RTRBR3lzZUx0Nk1WekZmXz…

Google News hu, 16 Jul 2026

Why Is VivoSim Labs Stock Falling Thursday? - Benzinga

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOVDNDZ2s2ejZvYUJPY1o5aERZc3ctQXFyRmZTYWZPeEE0d3h6QzZsdWRDbHVNRThLOTZSQkY4LTJ5WFc4T210eURMS3F1YVVlLVUzX3h4NnlTNTBOVWZBOFU5cFB3UEpFVDJrWWNhbDBnOUV1RzJrVWdjSHh3c054YkZvRzNGcm8tNWNkWG…

Google News hu, 16 Jul 2026

VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNnFJNm5wY1M3enNSODNja2h6REZxSTF2WnVPY3UyLVpKTEdUa0JrN2p0SmZIWjR1TkpaM0xfZWNMMVpmSU1LMk54S3BCaU03bUZwVmJfS3dpejlFdGZjemxqaHNySmV1UU9EYlBWUHhkalNWX0h2VURoOE1TY3VQV2NuS0JjU1k0SmpjRE…

Google News ue, 26 May 2026

VIVS - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5oS1RmeDVfcEZzc2V0bHloNzVfUS1hNGQ5cGFJZ29VMlh0ZUVpdEN1eW94dDlLZFJVZnJZRmMtdjg3ZFNCY3c?oc=5" target="_blank">VIVS</a>  <font color="#6f6f6f">Finviz</font>…

Google News Wed, 15 Jul 2026

VIVS Stock Whipsaws As Traders Target Volatile Moves - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5pNWgtdnRVV2k5eXhYbHVucjlWMFR1OEZHeEhEOENFTVIyOHBrTE4zdXBlZUxYTktGSk9QZDJIQWswTWJpRVpuZWdJUG9ReWdQZnVyZmNSemJSTFdLYzNUQTVtLXVwbjY0dzJjdUZlMHNfZjBGUVcybA?oc=5" target="_blank">VIVS …

VIVS — Frequently Asked Questions

What is the current share price of VivoSim Labs, Inc. (VIVS)?

As of 2026-09-19 21:16 PDT, VivoSim Labs, Inc. (VIVS) trades at $0.28 on NasdaqCM. Its 52-week range is $0.28 to $4.78.

What is the market capitalisation of VIVS?

VivoSim Labs, Inc. (VIVS) has a market capitalisation of $3.75M on NasdaqCM.

What is the P/E ratio of VIVS?

VIVS trades at a trailing price-to-earnings (P/E) ratio of -0.06. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.31.

Is VIVS a good stock to buy?

This page provides a data-driven analysis of VivoSim Labs, Inc. (VIVS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

VivoSim Labs, Inc. VIVS PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

VivoSim Labs (VIVS) News Flow - Moomoo

VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan

Why Is VivoSim Labs Stock Falling Thursday? - Benzinga

VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment - Quiver Quantitative

VIVS - Finviz

VIVS Stock Whipsaws As Traders Target Volatile Moves - StocksToTrade

VIVS — Frequently Asked Questions

What is the current share price of VivoSim Labs, Inc. (VIVS)?

What is the market capitalisation of VIVS?

What is the P/E ratio of VIVS?

Is VIVS a good stock to buy?

Explore More